




# Q1 2025 HIGHLIGHTS




“Ipsen has delivered a strong start to 2025, building further momentum in the transformation of our company”

*David Loew - Chief Executive Officer*

## TOTAL SALES



## GEOGRAPHIC BREAKDOWN



**North America**  
36%  
of total sales

**Europe**  
39%  
of total sales

**RoW**  
25%  
of total sales

## Q1 PIPELINE PROGRESS

- > Regulatory filing accepted by EMA<sup>2</sup> – tovorafenib
- > Phase I initiated - IPN01195 (a RAF inhibitor)

## UPCOMING MILESTONES

**CABOMETRYX**  
CABINET trial


Regulatory decision in E.U. for advanced pNETs<sup>3</sup> and epNETs<sup>4</sup>

**FIDRISERTIB**  
FALKON trial

Readout of the pivotal Phase IIb trial in FOP<sup>5</sup>

**LANT<sup>6</sup>**  
LANTIC trial

Proof-of-concept data readout, evaluating its potential in aesthetics



<sup>1</sup> At constant exchange rates <sup>2</sup> European Medicines Agency <sup>3</sup> pancreatic NeuroEndocrine Tumors <sup>4</sup> extra-pancreatic NeuroEndocrine Tumors <sup>5</sup> Fibrodysplasia ossificans progressiva <sup>6</sup> Long-Acting NeuroToxin